Metagenomi Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
MGX$0.72+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share data)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $102,558 | $140,603 |
| Available-for-sale marketable securities | 224,847 | 130,579 |
| Accounts receivable | 2,082 | 2,451 |
| Prepaid expenses and other current assets | 6,156 | 4,640 |
| Total current assets | 335,643 | 278,273 |
| Property and equipment, net | 20,960 | 21,542 |
| Long-term investments | 10,676 | 10,676 |
| Operating lease right-of-use assets | 42,497 | 43,611 |
| Other assets | 379 | 5,492 |
| Restricted cash | 5,248 | 5,248 |
| Total assets | $415,403 | $364,842 |
| Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $6,843 | $1,791 |
| Income tax payable | 3,266 | 3,266 |
| Accrued expenses and other current liabilities | 7,079 | 11,472 |
| Current portion of operating lease liabilities | 4,382 | 3,427 |
| Collaboration advance | 837 | 837 |
| Deferred revenue | 48,294 | 48,068 |
| Total current liabilities | 70,701 | 68,861 |
| Non-current portion of operating lease liabilities | 43,680 | 44,802 |
| Deferred revenue, non-current | 20,310 | 30,926 |
| Other non-current liabilities | 5,079 | 5,079 |
| Total liabilities | 139,770 | 149,668 |
| Commitments and contingencies (Note 8) | ||
| Redeemable convertible preferred stock: zero shares authorized, issued and outstanding as of March 31, 2024; 41,813,375 shares authorized, issued and outstanding as of December 31, 2023; liquidation preference of $352,044 as of December 31, 2023 | — | 350,758 |
| Stockholders equity (deficit): | ||
| Preferred stock: $0.0001 par value; 10,000,000 shares and zero shares authorized as of March 31, 2024 and December 31, 2023, respectively; zero shares issued and outstanding | — | — |
| Common stock: $0.0001 par value; 500,000,000 shares and 66,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 37,468,078 and 3,404,585 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 4 | — |
| Additional paid-in-capital | 445,999 | 9,457 |
| Accumulated other comprehensive loss | (278) | (97) |
| Accumulated deficit | (170,092) | (144,944) |
| Total stockholders’ equity (deficit) | 275,633 | (135,584) |
| Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) | $415,403 | $364,842 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.